Form 4: Kezar Life Sciences Director Acquires 50,000 Stock Options
SEC Form 4 Filing
Director Elizabeth Garner acquired 50,000 stock options in Kezar Life Sciences, Inc. on June 20, 2024.
Summary
- Elizabeth Garner, a director of Kezar Life Sciences, Inc., acquired 50,000 stock options on June 20, 2024.
- The options have an exercise price of $0.67.
- The options vest 100% on June 20, 2025, contingent upon continued service.
- The options expire on June 19, 2034.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it reflects a standard transaction (stock option grant) for a company director. It doesn't inherently indicate positive or negative implications for the company's performance.
Industry Context
This filing is a routine disclosure of a director's stock option grant, which is a common practice in publicly traded companies to incentivize and align the interests of directors with those of shareholders.
Stakeholder Impact
- The stock option grant aligns the director's interests with those of shareholders, incentivizing them to work towards increasing the company's value.
Key Dates
| Date | Description |
|---|---|
| 06/20/2024 | Date of earliest transaction: acquisition of stock options |
| 06/20/2025 | Vesting date for 100% of the stock options, contingent upon continued service |
| 06/19/2034 | Expiration date of the stock options |
| 06/21/2024 | Date of signature for the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.